Utkarsh H. Acharya

Hematology
460 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody.

Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody.

Journal: Blood reviews
Published: December 05, 2024

Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future.

Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future.

Journal: JCO oncology practice
Published: December 19, 2022

Improving compliance with appropriateness of testing for heparin-induced thrombocytopaenia: a quality improvement report.

Improving compliance with appropriateness of testing for heparin-induced thrombocytopaenia: a quality improvement report.

Journal: BMJ open quality
Published: December 23, 2021

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Journal: Haematologica
Published: April 13, 2021

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.

Journal: Blood advances
Published: November 23, 2020

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).

Journal: Cancers
Published: November 12, 2020

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 16, 2020

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Journal: American journal of hematology
Published: April 26, 2019

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Journal: Expert review of hematology
Published: February 23, 2019

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Journal: Blood
Published: November 28, 2018

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Journal: Blood
Published: November 07, 2018

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy.

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy.

Journal: Bone marrow transplantation
Published: July 28, 2018
Showing 1-12 of 19

Last Updated: 09/26/2026